HFS
AMRX icon

Hantz Financial Services’s Amneal Pharmaceuticals AMRX Stock Holding History

Hantz Financial Services’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$41K Buy
+3,265
New +$43.8K ﹤0.01% 1623

Other funds holding AMRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Hantz Financial Services's AMRX Position: Q1 2026 in Review

Hantz Financial Services opened a new position in Amneal Pharmaceuticals (AMRX) in Q1 2026: 3,265 shares worth $41K. The stake represents ﹤0.01% of the portfolio and ranks #1623 among its holdings.

315 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

  • Hantz Financial Services held 3,265 shares of Amneal Pharmaceuticals worth $41K as of Q1 2026.
  • Amneal Pharmaceuticals was a new Hantz Financial Services position in Q1 2026.
  • Amneal Pharmaceuticals made up ﹤0.01% of Hantz Financial Services's portfolio in Q1 2026, its #1623 holding.
  • 315 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on Hantz Financial Services's 13F filing for Q1 2026, filed 1 May 2026.